Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,580.06
(
0.22%
)
US TECH 100
29,506.00
(
0.28%
)
Dow Jones
51,032.46
(
0.72%
)
Brent Oil
92.66
(
1.42%
)
Bitcoin
73,737.40
(
0.25%
)
News Focus
News Focus
Post# of 518980
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

RipperMagoo1

Send PM Follow Ignore
Followers 9
Posts 150
Boards Moderated 0
Alias Born 03/23/2020

RipperMagoo1

Re: MayoMobile post# 301275

Monday, 03/01/2021 8:26:52 PM

Monday, March 01, 2021 8:26:52 PM

Post# of 518980
Excellent reminder Mayo.

Patience for the right kind of patients. This careful recruiting process will pay off big time.

The 2 primary endpoints for the (hopefully pivotal) P2b/3 AD trial are:

1. ADCS-ADL As you point out, 2A trial looks extremely promising especially for high dose S1 wt + APEO3 patients.

2. ADAS-Cog 2A results shown on slide 21 too. We also got a sneak preview of this in the placebo controlled PDD study. p=.003. 70% correlation of Episodic Memory deterioration to ADAS-Cog deterioration.

Who in their right mind would bet against this AD trial not meeting the primary endpoints? Not I!

No need for an interim look. We got this.

Updated profile pic

At no point in your rambling, incoherent response were you even close to anything that could be considered a rational thought. Everyone in this room is now dumber for having listened to it. I award you no points, and may God have mercy on your soul.

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent AVXL News
More AVXL News